Business Description
Clarity Pharmaceuticals Ltd
ISIN : AU0000165375
Total Employee Number:
70Description
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.91 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -26.3 | |||||
3-Year EPS without NRI Growth Rate | -27.9 | |||||
3-Year FCF Growth Rate | -47.1 | |||||
3-Year Book Growth Rate | -7.6 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 19.04 | |||||
9-Day RSI | 26.43 | |||||
14-Day RSI | 29.77 | |||||
3-1 Month Momentum % | -21.45 | |||||
6-1 Month Momentum % | -14.43 | |||||
12-1 Month Momentum % | 30.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.43 | |||||
Quick Ratio | 11.43 | |||||
Cash Ratio | 10.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.5 | |||||
Shareholder Yield % | -28.58 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -64.17 | |||||
ROA % | -58.52 | |||||
ROIC % | -892.63 | |||||
3-Year ROIIC % | -640.64 | |||||
ROC (Joel Greenblatt) % | -1324.5 | |||||
ROCE % | -70.74 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.02 | |||||
Price-to-Tangible-Book | 3.02 | |||||
EV-to-EBIT | -4.72 | |||||
EV-to-Forward-EBIT | -3.17 | |||||
EV-to-EBITDA | -4.73 | |||||
EV-to-Forward-EBITDA | -3.18 | |||||
EV-to-Forward-Revenue | 18.68 | |||||
EV-to-FCF | -6.91 | |||||
| Price-to-Net-Current-Asset-Value | 3.02 | |||||
| Price-to-Net-Cash | 3.41 | |||||
Earnings Yield (Greenblatt) % | -21.19 | |||||
FCF Yield % | -9.83 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CLRPF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Clarity Pharmaceuticals Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.185 | ||
| Beta | 2.8356 | ||
| 3-Year Sharpe Ratio | 0.8 | ||
| 3-Year Sortino Ratio | 1.72 | ||
| Volatility % | 98.69 | ||
| 14-Day RSI | 29.77 | ||
| 14-Day ATR ($) | 0.111288 | ||
| 20-Day SMA ($) | 1.598425 | ||
| 12-1 Month Momentum % | 30.43 | ||
| 52-Week Range ($) | 1.232 - 3.6 | ||
| Shares Outstanding (Mil) | 372.97 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Clarity Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Clarity Pharmaceuticals Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Clarity Pharmaceuticals Ltd Frequently Asked Questions
What is Clarity Pharmaceuticals Ltd(CLRPF)'s stock price today?
The current price of CLRPF is $1.33. The 52 week high of CLRPF is $3.60 and 52 week low is $1.23.
When is next earnings date of Clarity Pharmaceuticals Ltd(CLRPF)?
The next earnings date of Clarity Pharmaceuticals Ltd(CLRPF) is .
Does Clarity Pharmaceuticals Ltd(CLRPF) pay dividends? If so, how much?
Clarity Pharmaceuticals Ltd(CLRPF) does not pay dividend.
Guru Commentaries on OTCPK:CLRPF
No articles.
Press Release
Articles on Clarity Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers